Education
About Us
Working with TipRanks
Follow Us
RedHill Biopharma (RDHL)
NASDAQ:RDHL
Total Valuation
RedHill Biopharma has a market cap or net worth of $2.77M. The enterprise value is ―.
Market Cap$2.77M
Enterprise Value―
Share Statistics
RedHill Biopharma has 1,769,120 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding1,769,120
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
RedHill Biopharma’s return on equity (ROE) is 1.77 and return on invested capital (ROIC) is 381.84%.
Return on Equity (ROE)1.77
Return on Assets (ROA)-0.46
Return on Invested Capital (ROIC)381.84%
Return on Capital Employed (ROCE)3.50
Revenue Per Employee229.80K
Profits Per Employee-236.23K
Employee Count35
Asset Turnover0.45
Inventory Turnover0.87
Valuation Ratios
The current PE Ratio of RedHill Biopharma is -0.01. RedHill Biopharma’s PEG ratio is <0.01.
PE Ratio-0.01
PS Ratio0.59
PB Ratio-0.02
Price to Fair Value-0.02
Price to FCF-0.01
Price to Operating Cash Flow-0.01
PEG Ratio<0.01
Income Statement
In the last 12 months, RedHill Biopharma had revenue of 8.04M and earned -8.27M in profits. Earnings per share was -1.28.
Revenue8.04M
Gross Profit4.85M
Operating Income-14.61M
Pretax Income-8.27M
Net Income-8.27M
EBITDA-7.59M
Earnings Per Share (EPS)-1.28
Cash Flow
In the last 12 months, operating cash flow was -26.22M and capital expenditures -29.00K, giving a free cash flow of -23.83M billion.
Operating Cash Flow-26.22M
Free Cash Flow-23.83M
Free Cash Flow per Share-13.47
Dividends & Yields
RedHill Biopharma pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.10
52-Week Price Change-79.70%
50-Day Moving Average3.32
200-Day Moving Average7.06
Relative Strength Index (RSI)38.09
Average Volume (3m)348.58K
Important Dates
RedHill Biopharma upcoming earnings date is May 13, 2025, TBA Not Confirmed.
Last Earnings DateApr 10, 2025
Next Earnings DateMay 13, 2025
Ex-Dividend Date―
Financial Position
RedHill Biopharma as a current ratio of 0.54, with Debt / Equity ratio of -7.60%
Current Ratio0.54
Quick Ratio0.37
Debt to Market Cap0.00
Net Debt to EBITDA0.56
Interest Coverage Ratio-265.69
Taxes
In the past 12 months, RedHill Biopharma has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
RedHill Biopharma EV to EBITDA ratio is -4.74, with an EV/FCF ratio of -3.84.
EV to Sales4.47
EV to EBITDA-4.74
EV to Free Cash Flow-3.84
EV to Operating Cash Flow-3.84
Balance Sheet
RedHill Biopharma has $7.01M in cash and marketable securities with $0.00 in debt, giving a net cash position of -$4.73M billion.
Cash & Marketable Securities$7.01M
Total Debt$0.00
Net Cash-$4.73M
Net Cash Per Share-$2.67
Tangible Book Value Per Share-$1.58
Margins
Gross margin is 60.31%, with operating margin of -181.69%, and net profit margin of -102.80%.
Gross Margin60.31%
Operating Margin-181.69%
Pretax Margin-102.80%
Net Profit Margin-102.80%
EBITDA Margin-94.42%
EBIT Margin-102.11%
Analyst Forecast
The average price target for RedHill Biopharma is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast―
EPS Growth Forecast―